List of works by Aurélien Marabelle

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

scientific article published oln 16 November 2016

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

scientific article

A tribute to the life and career of Holbrook Kohrt

scientific article

Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy

scientific article published in March 2017

Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model

scientific article published on October 2008

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

scientific article published on 18 August 2017

Biomarkers associated with checkpoint inhibitors

scientific article published on 27 April 2016

CD34+ immunoselection of autologous grafts for the treatment of high‐risk neuroblastoma

scientific article published on 01 January 2011

Cabergoline therapy of paraneoplastic Cushing syndrome in children

scientific article published on September 2010

Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.

scientific article published on 8 September 2017

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

scientific article

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

scientific article

Circulating T-cell immunosenescence in advanced non-small cell lung cancer patients treated with single agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy

scientific article published on 04 September 2020

Clear cell ependymoma with trisomy 19 developing bone metastases

scientific article

Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.

scientific article

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients

scientific article

Combination strategies to enhance antitumor ADCC.

scientific article published on May 2012

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

scientific article published on June 2013

Depleting tumor-specific Tregs at a single site eradicates disseminatedtumors.

scientific article published in November 2013

Design and conduct of early clinical studies of immunotherapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)

scientific article published on 21 February 2020

Detection of tumor ALK status in neuroblastoma patients using peripheral blood

scientific article

Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer

scientific article published in 2022

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers

scientific article published on 01 June 2020

Focal nodular hyperplasia of the liver in patients previously treated for pediatric neoplastic diseases

scientific article published on July 2008

Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis.

scientific article

Holbrook Kohrt: In Memoriam (1977-2016).

scientific article

Hypercalcemia and 13-cis-retinoic acid in post-consolidation therapy of neuroblastoma

scientific article published in February 2009

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine

scientific article published on 24 August 2017

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

scientific article

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy

scientific article published on 23 May 2017

Immune responses during COVID-19 infection

scientific article published on 25 August 2020

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

scientific article

Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine

scientific article published on November 2012

Immunodynamics of explanted human tumors for immuno-oncology

scientific article published on 29 December 2020

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

scientific article

Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop

scientific article published on 19 May 2016

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

scientific article published on 29 January 2016

Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm

scientific article published on 07 July 2020

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

scientific article published on 7 April 2018

In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer

scientific article

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: Reactivation of tuberculosis after anti PD-1 treatment

scientific article published on 18 December 2017

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

scientific article

Interventional radiology for local immunotherapy in oncology

scientific article published on 08 January 2021

Intratumoral Immunotherapy: from Trial Design to Clinical Practice

scientific article published on 17 September 2020

Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity

scientific article published on 21 August 2013

Intratumoral immunization: a new paradigm for cancer therapy

scientific article published on April 2014

Intratumoral immunotherapy: using the tumor as the remedy

scientific article published in December 2017

Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer

scientific article published on 13 September 2017

Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors

scientific article published on 7 February 2018

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

scientific article

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.

scientific article published on 8 June 2016

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

scientific article

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients

scientific article published on 25 April 2016

New insights into the mechanism of action of immune checkpoint antibodies

scientific article published on 3 August 2014

Paradigm shift in oncology: targeting the immune system rather than cancer cells

scientific article

Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection

scientific article published on 23 May 2019

Pattern recognition receptors: immune targets to enhance cancer immunotherapy

scientific article

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

scientific article

Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination

scientific article published on 01 August 2020

Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies

scientific article published on 01 June 2020

Predictors of responses to immune checkpoint blockade in advanced melanoma

scientific article published on 19 September 2017

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

scientific article

Prime time for immune-checkpoint targeted therapy at ASCO 2015

scientific article

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer

scientific article published on 13 May 2016

Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

scientific article published on 06 July 2021

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

scientific article

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

scientific article published on 20 July 2016

Rationale for anti-OX40 cancer immunotherapy

scientific article

Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade

scientific article published on 01 October 2019

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

scientific article published on 9 June 2017

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

scientific article published on 01 October 2020

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

scientific article published on 10 January 2018

Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues

scientific article

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

scientific article published on 03 September 2019

T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition

scientific article published on October 2015

Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy

scientific article published on 08 September 2011

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

scientific article published on 10 April 2016

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

scientific article

The oncolytic compound LTX-401 targets the Golgi apparatus

scientific article published on 10 November 2017

The oncolytic compound LTX-401 targets the Golgi apparatus.

scientific article published on 2 September 2016

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

scientific article published on 15 April 2016

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

scientific article

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

scientific article published on January 2015

Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy

scientific article

Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

scientific article

Two cases of immune thrombocytopenia associated with pembrolizumab.

scientific article

[What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].

scientific article published on 28 March 2016